Mubadala Bio expands women’s health portfolio with launch of new hormone therapy

Mubadala Bio has launched dydrogesterone, an in-demand hormone therapy through this new drug the firm expands its women’s health portfolio, one of its core therapy areas.

Dydrogesterone is a synthetic form of progesterone and is used to support hormone balance in women. It is also commonly prescribed to help manage certain fertility-related conditions and menstrual disorders.

Fertility and reproductive health have become areas of growing focus, reflecting broader demographic and societal trends and reinforcing the importance of access to well-established, trusted therapies.

Dr. Bakheet Al Katheeri, CEO of Mubadala's UAE Investments Platform and Chairman of Mubadala Bio, said: “This milestone reflects Mubadala’s long-term commitment to building a national life sciences champion. Producing highly needed medical therapies locally strengthens the UAE’s pharmaceutical capabilities while supporting national health priorities.”

Dr. Essam Mohamed, CEO of Mubadala Bio, said: “At Mubadala Bio, we are supporting the life sciences ecosystem in the UAE by enhancing drug security and expanding access to highly demanded treatments. The local production of this medication aligns with our mission to provide better health, closer for all.”

Hamad Husein Al Marzooqi, Deputy CEO of Mubadala Bio, commented: “Women’s health is one of our main priorities and is central to the wellbeing of our society. By bringing the production of this essential treatment closer to home, we are improving access to key medications for women across the UAE.”

The local production of dydrogesterone therefore represents not only an important milestone, but a timely contribution to supporting women’s health across the country.

It is also mentioned that Mubadala Bio, a life sciences company dedicated to pursuing better health outcomes for the UAE and beyond. As a catalyst for progress and innovation, we are accelerating the growth of the life sciences ecosystem by enhancing drug security and expanding access to affordable, essential treatments. Operating through two core verticals, Integrated Biopharma and Pharma Logistics across the UAE, Asia, Africa, and Europe, we are driving impact both locally and globally.